United Therapeutics (BSP:U2TH34) Inventories, Finished Goods: R$568 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:U2TH34 United Therapeutics Corp BSP:U2TH34
65 GF Score
Price R$133.00
GF Value R$96.72
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Inventories, Finished Goods?

United Therapeutics BSP:U2TH34 65 Inventories, Finished Goods is R$568 Mil as of Mar. 2026. GuruFocus rates BSP:U2TH34 with a GF Score™ of 65/100 and a GF Value™ of R$96.72 (Significantly Overvalued). The stock has 7 warning signs investors should review.

United Therapeutics's quarterly finished goods increased from Sep. 2025 (R$593 Mil) to Dec. 2025 (R$639 Mil) but then declined from Dec. 2025 (R$639 Mil) to Mar. 2026 (R$568 Mil).

United Therapeutics's annual finished goods increased from Dec. 2023 (R$273 Mil) to Dec. 2024 (R$580 Mil) and increased from Dec. 2024 (R$580 Mil) to Dec. 2025 (R$639 Mil).

United Therapeutics Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Inventories, Finished Goods Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 250.51 265.94 272.92 579.60 639.41

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 558.54 571.22 592.61 639.41 567.94
BSP:U2TH34
65GF Score
United Therapeutics Corp BSP:U2TH34
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of R$568 Mil mean?
United Therapeutics (BSP:U2TH34) has a Inventories, Finished Goods of R$568 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Inventories, Finished Goods too high?
United Therapeutics' current Inventories, Finished Goods is R$568 Mil. Overall, United Therapeutics has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Inventories, Finished Goods compare to VTRS and NBIX?
United Therapeutics' Inventories, Finished Goods of R$568 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on United Therapeutics and its competitors. United Therapeutics's current Inventories, Finished Goods is R$568 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (BSP:U2TH34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$96.72, compared to a current price of R$133.00 — trading 37.5% above its estimated fair value. The current Inventories, Finished Goods is R$568 Mil. United Therapeutics' overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For United Therapeutics (BSP:U2TH34), the current Inventories, Finished Goods is R$568 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (BSP:U2TH34) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of R$133.00 is trading 37.5% above its estimated GF Value™ of R$96.72. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for BSP:U2TH34:

  • Inventories, Finished Goods: R$568 Mil
  • GF Value™: R$96.72 vs. price of R$133.00 (37.5% above fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the BSP:U2TH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTHR:USAUTH:Germany
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
65GF Score

Get the complete analysis for BSP:U2TH34

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$133.00
Price
R$96.72
GF Value